Baird Reiterates an 'Outperform' on Affymax (AFFY); Remain Buyers Ahead of Hematide Phase III Readouts
Tweet Send to a Friend
Baird reiterates an 'Outperform' rating on Affymax (Nasdaq: AFFY), price target $30.
Baird analyst says, "We remain buyers of AFFY ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Baird analyst says, "We remain buyers of AFFY ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
